p53 suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line

Journal of Cellular Physiology

Volumn 226, Issue 12, 2011, Pages 3433-3441

  Tian, Baolei ^a   Liu, Jilai ^a   Liu, Bin ^a   Dong, Yan ^a   Liu, Jinfeng ^a   Song, Yi ^a   Sun, Zhixian ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; HISTONE DEACETYLASE 2; LUNG RESISTANCE PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; Y BOX BINDING PROTEIN 1;

ARTICLE; BINDING SITE; BREAST TUMOR; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CHROMATIN IMMUNOPRECIPITATION; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CISPLATIN; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HISTONE DEACETYLASE 2; HUMANS; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; VAULT RIBONUCLEOPROTEIN PARTICLES; Y-BOX-BINDING PROTEIN 1;

EID: 80053168793     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22700     Document Type: Article

References (31)

1. Bargou RC, Jürchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B, Royer HD. 1997. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3: 447-450.
2. Berger W, Steiner E, Grusch M, Elbling L, Micksche M. 2009. Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci 66: 43-61.
3. Bouhamyia L, Chantot-Bastaraud S, Zaidi S, Roynard P, Prengel C, Bernaudin JF, Fleury-Feith J. 2007. Immunolocalization and cell expression of lung resistance-related protein (LRP) in normal and tumoral human respiratory cells. J Histochem Cytochem 55: 773-782.
4. Diestra JE, Condom E, Del Muro XG, Scheffer GL, Pérez J, Zurita AJ, Muñoz-Segui J, Vigués F, Scheper RJ, Capellá G, et al. 2003. Expression of multidrug resistance proteins p-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: Biological and clinical implications. J Urol 170: 1383-1387.
5. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, O'Connor PM. 1995. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654.
6. Guan Z, Shen Q. 2006. Construction of a middle fragment-deleted class II molecule transactivater mutant by modified OE-PCR technique. Acad J Sec Mil Med Univ 27: 1014-1017.
7. Han J, Li WM, Tang FM, Pu D, Chen WB. 2008. Effects of hnRN PB1 siRNA on the express ion of p 53 in human lung adenocarcinoma cell line A549. J Sichuan Univ (Med Sci Edi) 39: 812-814.
8. Harms KL, Chen X. 2007. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 67: 3145-3152.
9. Homer C, Knight DA, Hananeia L, Sheard P, Risk J, Lasham A, Royds JA, Braithwaite AW. 2005. Y-box factor YB1 controls p53 apoptotic function. Oncogene 24: 8314-8125.
10. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC. 2005. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395-404.
11. Husson H, Carideo EG, Neuberg D, Schultze J, Munoz O, Marks PW, Donovan JW, Chillemi AC, O'Connell P, Freedman AS. 2002. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 99: 282-289.
12. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21: 6236-6245.
13. Izquierdo MA, Scheffer GL, Flens MJ, Shoemaker RH, Rome LH, Scheper RJ. 1996. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 19: 191-197.
14. Kong LB, Siva AC, Rome LH, Stewart PL. 1999. Structure of the vault, a ubiquitous cellular component. Structure 7: 371-379.
15. Lange C, Walther W, Schwabe H, Stein U. 2000. Cloning and initial analysis of the human multidrug resistance-related MVP/LRP gene promoter. Biochem Biophys Res Commun 278: 125-133.
16. Lara PC, Lloret M, Clavo B, Apolinario RM, Henríquez-Hernández LA, Bordón E, Fontes F, Rey A. 2009. Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat Oncol 4: 29.
17. Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite AW, Watson J. 2003. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem 278: 35516-35523.
18. Li P, Wang D, Yao H, Doret P, Hao G, Shen Q, Qiu H, Zhang X, Wang Y, Chen G, et al. 2010. Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 29: 3153-3162.
19. Li Z, Fortin Y, Shen SH. 2009. Forward and robust selection of the most potent and noncellular toxic siRNAs from RNAi libraries. Nucleic Acids Res 37: e8.
20. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. 2008. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 68: 2375-2383.
21. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. 2002. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622.
22. Mossink MH, van Zon A, Fränzel-Luiten E, Schoester M, Kickhoefer VA, Scheffer GL, Scheper RJ, Sonneveld P, Wiemer EA. 2002. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res 62: 7298-7304.
23. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, Tsuneyoshi M, Kuwano M, Iwamoto Y. 1998. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 4: 2273-2277.
24. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, Kuwano M, Kohno K. 1996. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56: 4224-4228.
25. Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T, Kuwano M, Kohno K. 2000. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 19: 6194-6202.
26. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P. 1993. Overexpression of a M® 110, 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479.
27. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ. 2000. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12: 550-556.
28. Shimamoto Y, Sumizawa T, Haraguchi M, Gotanda T, Jueng HC, Furukawa T, Sakata R, Akiyama S. 2006. Direct activation of the human major vault protein gene by DNA-damaging agents. Oncol Rep 15: 645-652.
29. Stein U, Bergmann S, Scheffer GL, Scheper RJ, Royer HD, Schlag PM, Walther W. 2005. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 24: 3606-3618.
30. Slovak ML, Ho JP, Cole SP, Deeley RG, Greenberger L, de Vries EG, Broxterman HJ, Scheffer GL, Scheper RJ. 1995. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55: 4214-4219.
31. Zhang YF, Homer C, Edwards SJ, Hananeia L, Lasham A, Royds J, Sheard P, Braithwaite AW. 2003. Nuclear localization of Y-box factor YB1 requires wild-type p53. Oncogene 22: 2782-2794.